This trial is evaluating whether Prefrontal EEG (VEEGix by NeuroServo) will improve 1 primary outcome and 2 secondary outcomes in patients with Delirium. Measurement will happen over the course of up to five days after the operation.
This trial requires 160 total participants across 2 different treatment groups
This trial involves 2 different treatments. Prefrontal EEG (VEEGix By NeuroServo) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Overall the results are encouraging and preliminary results suggest that the number of delirium cases that responded to treatments was higher than those that did not. In a recent study, findings suggest a possible role of cognitive-behavior therapy in the treatment of delirium.
Patients with delirum have deficits in cognitive function and memory, they are slower to respond to stimuli, and they are more likely to be restrained in their surroundings. The most reliable signs for differentiating delirium from dementia are the lack of alertness and a lack of awareness.
Data from a recent study, delirium occurred more often in ICU patients who previously had experienced delirium, were elderly, and had a history of dementia. There was a higher frequency of delirium and more severe functional decline in the delirium group.
There is a significant increase in the incidence and prevalence of delirium over time. The average number of admissions for delirium increased from 9.4% in 1986 to 4.6% in 2011. The most rapid and dramatic increase was in admissions for elderly patients hospitalized for an acute exacerbation of chronic obstructive pulmonary disease since 1989.
Delirium is a common disorder among older adults. The most common causes for delirium included functional neurological deficit and delirium caused by drugs. In elderly individuals, the incidence of delirium is high compared with younger citizens. People who have a history of neurological decline and dementia are much more likely to experience delirium. Delirium is a strong risk factor for 1-year mortality, even more so than the severity of physical dysfunction.
Common treatments for delirium include nonpharmacologic agents (e.g., nonpharmacologic sedation, antipsychotic agents, and benzodiazepines); hypnotics (e.g., antipsychotics, benzodiazepines, and barbiturates); and pharmacologic agents (e.g., antidepressants, anticonvulsants, and anticholinergics), although these medications are no longer often used today. Some treatments like physical therapy, supplemental oxygen, and medications for nausea and constipation are often applied.
The NAC with eegix is typically associated with low seizure rate, low rate of coma, and low rate of delirium, even though it has a limited effect on the rate or duration of delirium. Data from a recent study shows the effectiveness of eegix as a drug for the NAC, and further confirms it as a good choice for a first-line drug for the treatment of delirium in elderly patients.
In this case-control trial of 20 hospitalized geriatric patients, we did not find evidence that veegix or an equivalent placebo treatment would have a beneficial effect in this patient group.
There is a lack of awareness of what predisposes to delirium among hospital staff and a lack of effective methods for identifying patients at risk of delirium. Measures to improve and educate healthcare workers in a hospital, as well as a system to identify patients at risk of delirium, should be implemented.
Brain waves are sensitive, and may be affected during anesthetic induction. We are assessing whether the use of a brain wave monitor will increase safety for patients undergoing induction.
PREM is a well-tolerated and effective sleep disorder therapy with a safety profile similar to hypnotic drugs, offering the potential for a broad use for sleep disorders.
The objective of this pilot study was to monitor alterations in prefrontal brain activities in delirious patients. These data indicate that the EEG analysis is useful for evaluating changes in the functions of cortical areas that may be correlated to delirious and delirium symptoms. In addition, the EEG data indicate that this evaluation is sensitive enough to detect early abnormalities in delirious patients, which cannot be detected using clinical assessments, such as scores of the mini-mental state examination. Therefore, EEG analysis is feasible as an evaluation tool of delirium. Moreover, EEG data may be useful for identifying the cause of delirium.